Resources from the same session
1718O - EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)
Presenter: Nicolas Penel
Session: Proffered paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
1719O - Multisarc: A randomized precision medicine study in advanced soft-tissue sarcomas
Presenter: Benjamin Verret
Session: Proffered paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1718O and 1719O
Presenter: Claudia María Valverde Morales
Session: Proffered paper session: Sarcoma
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Sarcoma
Resources:
Webcast
LBA78 - Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
Presenter: Hans Gelderblom
Session: Proffered paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
LBA79 - LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
Presenter: Jean-Yves Blay
Session: Proffered paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session: Sarcoma
Resources:
Webcast